PacBio's Q3 Loss Widens Amid Soaring Intangible Asset Amortization

Ticker: PACB · Form: 10-Q · Filed: 2025-11-06T00:00:00.000Z

Sentiment: bearish

Topics: Genomics, Biotechnology, Financial Performance, Intangible Assets, Net Loss, SEC Filing, 10-Q

TL;DR

**PacBio's massive intangible asset write-downs and ballooning losses make it a risky bet, despite stable revenue.**

AI Summary

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported a significant net loss of $506.005 million for the nine months ended September 30, 2025, a substantial increase from the $312.222 million loss in the prior year period. Total revenue saw a modest increase to $115.360 million for the nine months ended September 30, 2025, up from $114.790 million in the same period of 2024, driven by a rise in service and other revenue to $18.567 million, offsetting a slight decline in product revenue to $96.793 million. The company's operating loss widened dramatically to $512.664 million for the nine months ended September 30, 2025, compared to $321.285 million in the prior year, primarily due to a massive increase in amortization of acquired intangible assets to $363.708 million and impairment charges of $15.000 million. Cash and cash equivalents remained relatively stable at $56.467 million as of September 30, 2025, compared to $55.370 million at December 31, 2024, while total assets decreased from $1,260.447 million to $803.158 million over the same period, largely due to a reduction in investments and intangible assets. The company's stockholders' equity plummeted from $506.594 million at December 31, 2024, to $36.090 million at September 30, 2025, reflecting the substantial net loss.

Why It Matters

PacBio's significantly widened net loss and substantial decline in stockholders' equity signal deep concerns for investors, reflecting challenges in monetizing its advanced sequencing solutions despite a slight revenue increase. The massive amortization of acquired intangible assets and impairment charges suggest potential overvaluations or underperformance of past acquisitions, impacting the company's financial health and competitive standing in the genomics market. Employees might face uncertainty given the substantial losses, while customers could see impacts on future product development or support if financial pressures persist. The broader market will watch how PacBio navigates these financial headwinds, especially in a competitive landscape with other genomics technology providers.

Risk Assessment

Risk Level: high — The company reported a net loss of $506.005 million for the nine months ended September 30, 2025, a 62% increase from the $312.222 million loss in the prior year. This is primarily driven by a staggering $363.708 million in amortization of acquired intangible assets and $15.000 million in impairment charges, indicating significant issues with past acquisitions or asset valuations. Stockholders' equity has also dramatically decreased from $506.594 million to $36.090 million, highlighting severe financial deterioration.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to PACB given the substantial and increasing net losses, particularly those driven by significant intangible asset amortization and impairment charges. A thorough re-evaluation of the company's long-term viability and acquisition strategy is warranted before any new investment.

Financial Highlights

debt To Equity
21.25
revenue
$115,360,000
operating Margin
-444.34%
total Assets
$803,158,000
total Debt
$645,159,000
net Income
-$506,005,000
eps
N/A
gross Margin
25.32%
cash Position
$56,467,000
revenue Growth
0.49%

Revenue Breakdown

SegmentRevenueGrowth
Product revenue$96,793,000-5.16%
Service and other revenue$18,567,00045.75%

Key Numbers

Key Players & Entities

FAQ

What caused the significant increase in PACB's net loss for the nine months ended September 30, 2025?

PACB's net loss significantly increased to $506.005 million for the nine months ended September 30, 2025, primarily due to a substantial $363.708 million in amortization of acquired intangible assets and $15.000 million in impairment charges, compared to $13.377 million and $93.200 million respectively in the prior year period.

How did PACB's revenue perform in the nine months ended September 30, 2025?

PACB's total revenue for the nine months ended September 30, 2025, was $115.360 million, a slight increase from $114.790 million in the same period of 2024. This was driven by a rise in service and other revenue to $18.567 million, which offset a decline in product revenue to $96.793 million.

What is the current state of PACB's stockholders' equity?

PACB's total stockholders' equity dramatically decreased from $506.594 million as of December 31, 2024, to $36.090 million as of September 30, 2025. This significant reduction is a direct consequence of the substantial net loss incurred during the period.

What are the key changes in PACB's balance sheet assets?

PACB's total assets decreased from $1,260.447 million at December 31, 2024, to $803.158 million at September 30, 2025. This decline was largely driven by a reduction in investments from $334.561 million to $242.187 million and a significant decrease in intangible assets, net, from $389.572 million to $16.143 million.

How has PACB's operating loss changed year-over-year?

PACB's operating loss widened significantly, reaching $512.664 million for the nine months ended September 30, 2025, compared to an operating loss of $321.285 million for the same period in 2024. This deterioration is primarily attributable to increased amortization of acquired intangible assets and impairment charges.

What is the impact of amortization of acquired intangible assets on PACB's financials?

Amortization of acquired intangible assets had a profound impact on PACB's financials, increasing from $13.377 million for the nine months ended September 30, 2024, to $363.708 million for the same period in 2025. This massive increase was a primary driver of the expanded operating and net losses.

What is PACB's cash position as of September 30, 2025?

As of September 30, 2025, PACB reported cash and cash equivalents of $56.467 million, which is a slight increase from $55.370 million at December 31, 2024. Net cash used in operating activities for the nine months ended September 30, 2025, was $92.140 million.

Are there any significant changes in PACB's liabilities?

PACB's total liabilities increased from $753.853 million at December 31, 2024, to $767.068 million at September 30, 2025. Notable changes include an increase in operating lease liabilities, non-current, from $14.914 million to $54.300 million, and a decrease in contingent consideration liability, non-current, from $18.700 million to zero.

What is PACB's net loss per share for the nine months ended September 30, 2025?

PACB's basic and diluted net loss per share for the nine months ended September 30, 2025, was $(1.69). This is a significant increase from the $(1.15) net loss per share reported for the same period in 2024, reflecting the larger overall net loss.

What is the strategic outlook for PACB given these financial results?

Given the substantial net losses, particularly those driven by significant amortization of acquired intangible assets and impairment charges, PACB faces considerable pressure to demonstrate the value and profitability of its advanced sequencing solutions. The company's ability to improve its financial performance will depend on successful execution of its product strategy and effective management of its asset base.

Risk Factors

Industry Context

Pacific Biosciences of California, Inc. operates in the highly competitive life sciences and biotechnology sector, specifically focusing on DNA sequencing technology. The industry is characterized by rapid technological advancements, significant R&D investment, and a landscape dominated by both established players and innovative startups. Companies in this space often rely on strategic partnerships, intellectual property protection, and the ability to scale production and adoption of complex scientific instruments and services.

Regulatory Implications

As a biotechnology company, PACB is subject to stringent regulatory oversight from bodies like the FDA for any diagnostic or therapeutic applications of its technology. Compliance with data privacy regulations (e.g., HIPAA) is also crucial, especially if its sequencing data is used in clinical settings. Changes in healthcare policy or reimbursement rates for genetic testing could also impact market demand and revenue.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Amortization of acquired intangible assets
The systematic allocation of the cost of an intangible asset over its useful life. In this context, it refers to the expensing of intangible assets acquired through business combinations. (A major driver of the increased operating loss, accounting for $363.708 million in the nine months ended September 30, 2025.)
Impairment charges
A reduction in the carrying value of an asset when its fair value is less than its book value, indicating a permanent decline in value. (Contributed $15.000 million to the operating loss for the nine months ended September 30, 2025, though lower than the prior year's $93.200 million.)
Accumulated deficit
The cumulative net losses of a company that have not been offset by net income. It represents a negative balance in retained earnings. (Stood at a substantial $2,654,931,000 as of September 30, 2025, reflecting the company's history of losses.)
Convertible senior notes
Debt securities that can be converted into a predetermined amount of the issuer's equity at certain times. (Represents a significant portion of the company's liabilities ($645.159 million), providing capital but also carrying conversion risk for equity holders.)
Goodwill
An intangible asset that arises when a company acquires another company for a price greater than the fair value of its identifiable net assets. (The company holds $317.761 million in goodwill, which is subject to impairment testing and could lead to future charges if its value declines.)
Operating lease right-of-use assets
Assets recognized under accounting standards for leases, representing the right to use an underlying asset for the lease term. (These assets increased significantly to $42.583 million from $16.091 million, indicating new or expanded lease commitments.)
Deferred revenue
Revenue that has been received by a company but not yet earned, as the goods or services have not yet been delivered or performed. (The company has $16.049 million in current and $4.400 million in non-current deferred revenue, representing future revenue streams.)

Year-Over-Year Comparison

Compared to the prior year period, PACB has experienced a significant deterioration in its financial performance. Total revenue saw a marginal increase of 0.49% to $115.360 million for the nine months ended September 30, 2025, up from $114.790 million. However, the net loss widened substantially to $506.005 million from $312.222 million, and the operating loss grew from $321.285 million to $512.664 million, primarily due to a massive increase in amortization of acquired intangible assets. Stockholders' equity has plummeted from $506.594 million to $36.090 million, indicating severe financial strain. New risks related to the significant increase in amortization and impairment charges are now more prominent.

Filing Stats: 4,528 words · 18 min read · ~15 pages · Grade level 17.4 · Accepted 2025-11-06 16:04:20

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited): Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 6 Notes to Condensed Consolidated Financial Statements 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 27

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 39

Controls and Procedures

Item 4. Controls and Procedures 39

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 40

Risk Factors

Item 1A. Risk Factors 41

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 82

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 82

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 82

Other Information

Item 5. Other Information 83

Exhibits

Item 6. Exhibits 84

Signatures

Signatures 85 Q3 Fiscal 2025 Form 10-Q 2 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands, except par value) September 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents $ 56,467 $ 55,370 Investments 242,187 334,561 Accounts receivable, net 30,616 27,524 Inventory, net 53,153 58,755 Prepaid expenses and other current assets 11,513 18,781 Short-term restricted cash 300 690 Total current assets 394,236 495,681 Property and equipment, net 22,127 30,505 Operating lease right-of-use assets, net 42,583 16,091 Long-term restricted cash 1,532 1,532 Intangible assets, net 16,143 389,572 Goodwill 317,761 317,761 Other long-term assets 8,776 9,305 Total assets $ 803,158 $ 1,260,447 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 16,362 $ 16,590 Accrued expenses 29,172 22,595 Deferred revenue, current 16,049 13,864 Operating lease liabilities, current 621 10,026 Other liabilities, current 1,005 3,224 Total current liabilities 63,209 66,299 Deferred revenue, non-current 4,400 5,900 Contingent consideration liability, non-current — 18,700 Operating lease liabilities, non-current 54,300 14,914 Convertible senior notes, net, non-current 645,159 647,494 Other liabilities, non-current — 546 Total liabilities 767,068 753,853 Commitments and contingencies Stockholders' equity Preferred stock, $ 0.001 par value: Authorized 50,000 shares; No shares issued or outstanding — — Common stock, $ 0.001 par value: Authorized 1,000,000 shares; issued and outstanding 301,853 and 294,418 shares at September 30, 2025 and December 31, 2024, respectively 302 294 Additional paid-in capital 2,690,304 2,654,804 Accumulated other comprehensive income 415 422 Accumulated deficit ( 2,654,931 ) ( 2,148,926 ) Total stockholders' equity 36,090 506,594 Total liabilities and stockholders' equity $ 803,158 $ 1,260,447 See accompanying notes to the condensed consol

View on Read The Filing